10-K: Bristol-Myers Squibb Grants Restricted Stock Units with Multi-Year Vesting

Bristol-Myers Squibb has granted restricted stock units to employees under its 2021 Stock Award and Incentive Plan, with vesting periods ranging from one to five years.

Summary

• Bristol-Myers Squibb has granted restricted stock units (RSUs) to employees under the 2021 Stock Award and Incentive Plan.
• The awards vest over one to five years, depending on the specific agreement.
• Vesting is contingent upon continued employment with the company or its subsidiaries.
• The company may settle the RSUs in shares of common stock or cash.
• The agreements include non-competition and non-solicitation clauses.
• The agreements also outline the employees' responsibility for taxes related to the awards.
• The company retains the right to modify, amend, suspend, or terminate the plan at any time.
• The company is not providing any tax, legal, or financial advice regarding the awards.
• The agreements are governed by the laws of the State of Delaware.

Sentiment

Score: 7

Explanation: The document is a standard legal agreement for stock awards, with no particularly positive or negative sentiment. It is a routine part of employee compensation.

Positives

• The awards provide an opportunity for employees to acquire an ownership position in the company.
• The vesting periods encourage long-term employment with the company.
• The company has the flexibility to settle the awards in shares or cash.
• The agreements are designed to comply with Section 409A of the Internal Revenue Code.

Negatives

• The awards are subject to forfeiture if employment is terminated for misconduct or other detrimental conduct.
• The awards are subject to recoupment under the company's clawback policies.
• Employees are responsible for all taxes related to the awards, which may exceed the amount withheld by the company.
• The company is not providing any tax, legal, or financial advice regarding the awards.

Risks

• The value of the underlying shares of common stock is unknown and may decrease.
• The awards are subject to forfeiture if employment is terminated for misconduct or other detrimental conduct.
• The awards are subject to recoupment under the company's clawback policies.
• Employees are responsible for all taxes related to the awards, which may exceed the amount withheld by the company.
• The company is not providing any tax, legal, or financial advice regarding the awards.

Future Outlook

The company may modify, amend, suspend, or terminate the plan at any time to the extent permitted by the plan.

Management Comments

• The Compensation and Management Development Committee of the Board of Directors of Bristol-Myers Squibb Company (the Committee) has approved a grant to you of the Award as of March 10, 2024 (the Award Date) in the number specified on the Stock Plan Administrators website, subject to the terms, conditions, and restrictions set forth in this Agreement and the Plan.
• As consideration for grant of this Award, you shall remain in the continuous employment of the Company and/or its subsidiaries or affiliates for the entire Restricted Period or such lesser period as the Committee shall determine in its sole discretion, and no RSUs shall be delivered until after the completion of such Restricted Period or lesser period of employment by you (except as set forth in Section 2 hereof, as applicable).

Industry Context

The granting of stock-based compensation is a common practice in the pharmaceutical industry to incentivize employees and align their interests with those of the company's shareholders.

Comparison to Industry Standards

• The vesting schedules of one to five years are within the typical range for RSU grants in the pharmaceutical industry.
• The inclusion of non-competition and non-solicitation clauses is also a standard practice in the industry to protect the company's interests.
• The company's approach to tax withholding and compliance with Section 409A of the Internal Revenue Code is consistent with industry best practices.
• Many companies in the pharmaceutical industry use similar stock plans to attract and retain talent, including companies such as Pfizer, Merck, and Johnson & Johnson.

Stakeholder Impact

• Employees will be incentivized to remain with the company and contribute to its success.
• Shareholders will benefit from the alignment of employee interests with those of the company.
• The company will be able to attract and retain talent through competitive compensation packages.

Next Steps

• Employees must accept the terms of the agreement prior to the first vesting date.
• The company will determine the number of shares to be delivered upon vesting.
• The company will settle the awards within 60 days of the vesting date.

Key Dates

Keywords

restricted stock units, RSUs, stock award, vesting, stock plan, equity compensation, non-competition, non-solicitation, tax liability, forfeiture, recoupment